Psilocybin
Optimi Health Gets Permission to Supply MDMA, Psilocybin to Medical Program
The company has plans to become a full-fledged psychedelics manufacturer.
The post Optimi Health Gets Permission to Supply MDMA, Psilocybin to Medical…
Canadian psychedelics company Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) received the green light from federal officials to begin supplying MDMA and psilocybin to the government’s Special Access Program for seriously ill medical patients.
The permission was given by Health Canada through an amendment to Optimi Health’s dealer’s license, which will let the business take the next step in becoming a full-fledged psychedelics manufacturer and distributor, company executives said.
“Our consistent dedication over recent months has strengthened our capabilities in GMP psychedelics production,” CEO Bill Ciprick said in a statement. “The hard work during this time ensures that our in-house formulated drug candidates will be available to healthcare professionals, addressing the therapeutic needs of their patients.”
Karina Lahnakoski, director of quality and commercial strategies, added that the company is dedicated to producing quality psychedelic medicines.
“Safety, scale, and quality hold the key to our ability to cater to practitioners within Canada and Australia,” Lahnakoski said, referring to Optimi’s distribution agreement with Mind Medicine Australia.
Optimi began clinical trials on both MDMA and psilocybin products earlier this year.
The post Optimi Health Gets Permission to Supply MDMA, Psilocybin to Medical Program appeared first on Green Market Report.
psilocybin mdma psychedelic psychedelics cse mind medicine optimi health optimi health canada
-
Psychedelics1 week agoRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week agoAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week agoTryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week agoPassover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week agoatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week agoSilo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week agoPsilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment